Enanta Pharma

$71.27 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Enanta Pharma

Enanta Pharmaceuticals, Inc. is a biotechnology company. The Company uses chemistry-driven approach and drug discovery capabilities. The Company is focused on discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. The Company has clinical candidates for the disease targets, including respiratory syncytial virus (RSV), hepatitis B virus (HBV) and non-alcoholic steatohepatitis (NASH). It also conducts research in human metapneumovirus (hMPV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or coronavirus disease-2019 (COVID-19). The Company has discovered glecaprevir, a protease inhibitor discovered and developed through its collaboration with AbbVie for the treatment of chronic hepatitis C virus (HCV). Glecaprevir is co-formulated as part of AbbVie’s direct-acting antiviral (DAA), a combination treatment for HCV infection under the tradenames: MAVYRET and MAVIRET.

Stock Analysis

last close $70.96
1-mo return 34.7%
3-mo return 19.1%
avg daily vol. 205.83T
52-week high 102
52-week low 37.59
market cap. $1.5B
forward pe 12.2
annual div. -
roe -28.3%
ltg forecast -
dividend yield -
annual rev. $92M
inst own. 96.8%
baraka

Subscribe now for daily local and international financial news

Subscribe